Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jetrea

National Institute for Health and Care Excellence NICE logo

NICE turns down Opdivo for head and neck cancer

BMS’s nivolumab proves too costly for the NHS

Deal Watch March 2017

Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up

- PMLiVE

Focus on value: A prescription for pharma

The pricing debate demands a common language to be developed

- PMLiVE

Snapchat arrives at scientific meetings

And NICE becomes the first public health body to use the platform

- PMLiVE

Novartis gets lung cancer OK for Tafinlar/Mekinist combo

It can now be used to treat BRAF V600E-positive NSCLC patients in Europe

Novartis day

Novartis files CAR-T therapy in US, with swift review

CTL109 candidate gets FDA priority review status

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

Novartis day

What future for serelaxin after phase III miss?

Novartis' acute heart failure therapy misses two main endpoints

- PMLiVE

Novartis appoints new UK managing director

Haseeb Ahmad joins the firm from MSD

Novartis day

Could Cosentyx free psoriasis patients from treatment?

One in five patients on the Novartis treatment remained symptom-free for a year

Biogen Idec building

NICE backtracks on Biogen’s multiple sclerosis drug Zinbryta

Recommends the treatment after new cost effectiveness and a discount provided

Polyphor appoints new chief medical and development officer

Dr Debra Baker joins the firm from Novartis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links